Moxonidine for Postural Orthostatic Tachycardia Syndrome

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Postural Orthostatic Tachycardia SyndromeMoxonidine - Drug
Eligibility
18 - 55
Female
What conditions do you have?
Select

Study Summary

This trial is studying whether a blood pressure medication can help improve symptoms in people with postural tachycardia syndrome, which mostly affects young women and causes significant disability.

Eligible Conditions
  • Postural Orthostatic Tachycardia Syndrome

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: after 30 min supine to after 15 min upright (delta VOSS), 2-3 hours after placebo or moxonidine intake [delta (delta VOSS)].

Hour 3
Change in Orthostatic Change in Heart Rate [delta (delta HR)]
Hour 3
Change in Orthostatic Symptom Burden [delta (delta VOSS)]

Trial Safety

Trial Design

2 Treatment Groups

Moxonidine
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

48 Total Participants · 2 Treatment Groups

Primary Treatment: Moxonidine · Has Placebo Group · Phase < 1

Moxonidine
Drug
Experimental Group · 1 Intervention: Moxonidine · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Moxonidine
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: after 30 min supine to after 15 min upright (delta voss), 2-3 hours after placebo or moxonidine intake [delta (delta voss)].

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,592 Previous Clinical Trials
46,945,746 Total Patients Enrolled
10 Trials studying Postural Orthostatic Tachycardia Syndrome
442 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome
Vanderbilt University Medical CenterLead Sponsor
774 Previous Clinical Trials
601,069 Total Patients Enrolled
15 Trials studying Postural Orthostatic Tachycardia Syndrome
711 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome
André Diedrich, MDPrincipal InvestigatorVanderbilt University Medical Center
1 Previous Clinical Trials
48 Total Patients Enrolled
1 Trials studying Postural Orthostatic Tachycardia Syndrome
48 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome

Eligibility Criteria

Age 18 - 55 · Female Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
able to provide information that allows for an informed decision to be made.
not feeling lightheaded or dizzy when standing up quickly; normotension or hypertension (blood pressure ≤ 140/90 mmHg) They do not feel lightheaded or dizzy when standing up quickly and their blood pressure is normal or high.
Hormones released from the ovaries during the follicular phase stimulate the growth of the ovarian follicle and the production of estrogen.
, are at high risk for developing POTS related adverse cardiovascular events
This study includes female and male subjects aged 18-55 years.
The text states that a heart rate increase of ≥30 beats/min within 10 minutes of upright posture is indicative of POTS.
You have chronic symptoms that last for at least 6 months and are not caused by any other condition.

Who else is applying?

What state do they live in?
Hawaii100.0%
How old are they?
18 - 65100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%